Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
Anti-PVRIG and anti-TIGIT antibodies are provided.
1. A composition comprising an antigen binding domain that binds to human TIGIT (SEQ ID NO:97) comprising:
a) a variable heavy domain comprising SEQ ID NO:160; and
b) a variable light domain comprising SEQ ID NO:165.
2. A composition according to claim 1 wherein said composition is an antibody comprising:
a) a heavy chain comprising VH-CH1-hinge-CH2-CH3, wherein said VH comprises SEQ ID NO:160; and
b) a light chain comprising VL-VC, wherein said VL comprising SEQ ID NO:165 and VC is either kappa or lambda.
3. A composition according to claim 2 wherein the sequence said CH1-hinge-CH2-CH3 is selected from human IgG1, IgG2 and IgG4, and variants thereof.
4. A composition according to claim 2 wherein said heavy chain has SEQ ID NO:164 and said light chain has SEQ ID NO:169.
5. A composition according to claim 2 further comprising a second antibody that binds to a human checkpoint receptor protein.
6. A composition according to claim 5 wherein said second antibody binds human PD-1.
7. A composition according to claim 5 wherein said second antibody binds human PVRIG (SEQ ID NO:2).
8. A composition according to claim 7 wherein said second antibody comprises an antigen binding domain comprising a variable heavy domain comprising SEQ ID NO:5 and a variable light domain comprising SEQ ID NO:10.
9. A composition according to claim 7 wherein the heavy chain of said second antibody has SEQ ID NO:9 and the light chain of said second antibody has SEQ ID NO:14.
10. A composition according to claim 7 wherein said second antibody comprises an antigen binding domain comprising a variable heavy domain comprising SEQ ID NO:15 and a variable light domain comprising SEQ ID NO:20.
11. A composition according to claim 7 wherein the heavy chain of said second antibody has SEQ ID NO:19 and the light chain of said second antibody has SEQ ID NO:24.
12. A composition according to claim 7 wherein said second antibody comprises:
i) the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:5 and
ii) the v1CDR1, v1CDR2, and v1CDR3 from SEQ ID NO:10.
13. A composition comprising an antibody that binds to human TIGIT (SEQ ID NO:97) wherein said antibody comprises:
i) the vhCDR1, vhCDR2, and vhCDR3 from SEQ ID NO:160; and
ii) the v1CDR1, v1CDR2, and v1CDR3 from SEQ ID NO:165.
14. A composition according to claim 13 wherein said antibody comprises a CH1-hinge-CH2-CH3 region from human IgG1, IgG2, or IgG4, or variants thereof.
15. A composition according to claim 13 wherein said antibody comprises a VC region, wherein said VC is either kappa or lambda.
16. A composition according to claim 13 further comprising a second antibody that binds to a human checkpoint receptor protein.
17. A composition according to claim 16 wherein said second antibody binds human PD-1.
18. A composition according to claim 16 wherein said second antibody binds human PVRIG (SEQ ID NO:2).
19. A composition according to claim 18 wherein said second antibody comprises an antigen binding domain comprising a variable heavy domain comprising SEQ ID NO:5 and a variable light domain comprising SEQ ID NO:10.
20. A composition according to claim 18 wherein said second antibody comprises an antigen binding domain comprising a variable heavy domain comprising SEQ ID NO:15 and a variable light domain comprising SEQ ID NO:20.
21. A composition according to claim 18 wherein the heavy chain of said second antibody has SEQ ID NO:9 and the light chain of said second antibody has SEQ ID NO:14.
22. A composition according to claim 18 wherein the heavy chain of said second antibody has SEQ ID NO:19 and the light chain of said second antibody has SEQ ID NO:24.